These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

484 related articles for article (PubMed ID: 1375700)

  • 1. In vitro responsiveness to interleukins and theophylline of CD16+, CD56- natural killer cells in a patient with chronic granular lymphocyte disorder.
    Bayle C; Vitté-Mony I; Lang P; Pico J; Hercend T; Bertoglio J
    Leukemia; 1992 May; 6(5):470-6. PubMed ID: 1375700
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A comparative study of IL-12 (cytotoxic lymphocyte maturation factor)-, IL-2-, and IL-7-induced effects on immunomagnetically purified CD56+ NK cells.
    Naume B; Gately M; Espevik T
    J Immunol; 1992 Apr; 148(8):2429-36. PubMed ID: 1373169
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Differential responses to interleukin 2 define functionally distinct subsets of human natural killer cells.
    Baume DM; Robertson MJ; Levine H; Manley TJ; Schow PW; Ritz J
    Eur J Immunol; 1992 Jan; 22(1):1-6. PubMed ID: 1370410
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Natural killer cells activated by interleukin 2 treatment in vivo respond to interleukin 2 primarily through the p75 receptor and maintain the p55 (TAC) negative phenotype.
    Weil-Hillman G; Voss SD; Fisch P; Schell K; Hank JA; Sosman JA; Sugamura K; Sondel PM
    Cancer Res; 1990 May; 50(9):2683-91. PubMed ID: 1691679
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Morphological, phenotypic and functional characteristics of a pure population of CD56+ CD16- CD3- large granular lymphocytes generated from human duodenal mucosa.
    Pang G; Buret A; Batey RT; Chen QY; Couch L; Cripps A; Clancy R
    Immunology; 1993 Jul; 79(3):498-505. PubMed ID: 7691728
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Different mechanisms of activation of proliferating CD3+ cells in patients with lymphoproliferative disease of granular lymphocytes.
    Zambello R; Cassatella MA; Trentin L; Bulian P; Siviero F; Feruglio C; Agostini C; Vespignani M; Chisesi T; Pizzolo G
    Leukemia; 1991 Nov; 5(11):942-50. PubMed ID: 1835747
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Accumulation of CD16-CD56+ natural killer cells with high affinity interleukin 2 receptors in human early pregnancy decidua.
    Nishikawa K; Saito S; Morii T; Hamada K; Ako H; Narita N; Ichijo M; Kurahayashi M; Sugamura K
    Int Immunol; 1991 Aug; 3(8):743-50. PubMed ID: 1716974
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The CD56 adhesion molecule is the major determinant for detecting non-major histocompatibility complex-restricted cytotoxic mononuclear cells from the intestinal lamina propria.
    Van Tol EA; Verspaget HW; Peña AS; Kraemer CV; Lamers CB
    Eur J Immunol; 1992 Jan; 22(1):23-9. PubMed ID: 1370415
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Human pulmonary natural killer (NK) cells exhibit limited lymphokine-activated killer (LAK) activity.
    Yarbrough WC; Weissler JC
    Am J Respir Cell Mol Biol; 1989 Oct; 1(4):305-11. PubMed ID: 2483121
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Activation via the CD3 and CD16 pathway mediates interleukin-2-dependent autocrine proliferation of granular lymphocytes in patients with granular lymphocyte proliferative disorders.
    Hoshino S; Oshimi K; Teramura M; Mizoguchi H
    Blood; 1991 Dec; 78(12):3232-40. PubMed ID: 1835892
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Costimulatory signals are required for optimal proliferation of human natural killer cells.
    Robertson MJ; Manley TJ; Donahue C; Levine H; Ritz J
    J Immunol; 1993 Mar; 150(5):1705-14. PubMed ID: 7679691
    [TBL] [Abstract][Full Text] [Related]  

  • 12. In vitro generation and antitumor activity of adherent lymphokine-activated killer cells from the blood of patients with brain tumors.
    Whiteside TL; Wang YL; Selker RG; Herberman RB
    Cancer Res; 1988 Nov; 48(21):6069-75. PubMed ID: 2971433
    [TBL] [Abstract][Full Text] [Related]  

  • 13. In vitro interleukin 12 activation of peripheral blood CD3(+)CD56(+) and CD3(+)CD56(-) gammadelta T cells from glioblastoma patients.
    Fujimiya Y; Suzuki Y; Katakura R; Miyagi T; Yamaguchi T; Yoshimoto T; Ebina T
    Clin Cancer Res; 1997 Apr; 3(4):633-43. PubMed ID: 9815731
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Lymphokine-activated killer activity induced by in vivo interleukin 2 therapy: predominant role for lymphocytes with increased expression of CD2 and leu19 antigens but negative expression of CD16 antigens.
    Weil-Hillman G; Fisch P; Prieve AF; Sosman JA; Hank JA; Sondel PM
    Cancer Res; 1989 Jul; 49(13):3680-8. PubMed ID: 2471587
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Identification of a novel CD56- lymphokine-activated killer cell precursor in cancer patients receiving recombinant interleukin 2.
    McKenzie RS; Simms PE; Helfrich BA; Fisher RI; Ellis TM
    Cancer Res; 1992 Nov; 52(22):6318-22. PubMed ID: 1384959
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Analysis of lymphocyte phenotype and T cell receptor genotype in Felty's syndrome.
    Meliconi R; Kingsley GH; Pitzalis C; Sakkas L; Panayi GS
    J Rheumatol; 1992 Jul; 19(7):1058-64. PubMed ID: 1380988
    [TBL] [Abstract][Full Text] [Related]  

  • 17. CD56bright natural killer cell subsets: characterization of distinct functional responses to interleukin-2 and the c-kit ligand.
    Carson WE; Fehniger TA; Caligiuri MA
    Eur J Immunol; 1997 Feb; 27(2):354-60. PubMed ID: 9045904
    [TBL] [Abstract][Full Text] [Related]  

  • 18. CD16- CD56+ natural killer cells after bone marrow transplantation.
    Jacobs R; Stoll M; Stratmann G; Leo R; Link H; Schmidt RE
    Blood; 1992 Jun; 79(12):3239-44. PubMed ID: 1375847
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The effect of interleukin 2 and transforming growth factor-beta 2 (TGF-beta 2) on the proliferation and natural killer activity of decidual CD16- CD56bright natural killer cells.
    Saito S; Morii T; Enomoto M; Sakakura S; Nishikawa K; Narita N; Ichijo M
    Cell Immunol; 1993 Dec; 152(2):605-13. PubMed ID: 7504983
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A novel functional cell surface dimer (Kp43) expressed by natural killer cells and T cell receptor-gamma/delta+ T lymphocytes. I. Inhibition of the IL-2-dependent proliferation by anti-Kp43 monoclonal antibody.
    Aramburu J; Balboa MA; Ramírez A; Silva A; Acevedo A; Sánchez-Madrid F; De Landázuri MO; López-Botet M
    J Immunol; 1990 Apr; 144(8):3238-47. PubMed ID: 1691231
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 25.